Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration.

OBJECTIVE To evaluate risk factors for bladder cancer recurrence in a cohort of patients treated with radical nephroureterectomy (RNU). PATIENTS AND METHODS At 10 Canadian University Centers, we retrospectively evaluated data, between 1990 and 2010, from 743 patients who were free from bladder cancer and were previously treated with RNU for upper tract urothelial cancer. RESULTS Of 743 patients, 167 (22.5%) developed bladder tumors after a median time of 17.2 months after RNU. Multivariable analysis detected age (hazard ratio [HR] = 1.028; 95% CI: 1.010-1.046; P = 0.0018), tumor location in both the renal pelvis and the ureter (HR = 2.205; 95% CI: 1.355-3.589; P = 0.0015), the use of adjuvant systemic chemotherapy (HR = 2.309; 95% CI: 1.439-3.705; P = 0.0005), and laparoscopic surgery (HR = 1.876; 95% CI: 1.226-2.87; P = 0.0037) as risk factors for bladder cancer recurrence. Open excision of a bladder cuff (HR = 0.661; 95% CI: 0.453-0.965; P = 0.0319) and transurethral resection of the intramural ureter (HR = 0.548; 95% CI: 0.306-0.981; P = 0.0429) on comparison with extravesical resection decreased the risk of bladder cancer recurrence significantly. Major limitations were the retrospective design and partially missing data, although the significance of variables did not change in the imputation analysis. CONCLUSION Older patients, those with tumor location in both the renal pelvis and the ureter, and those treated with adjuvant systemic chemotherapy were found at higher risk for intravesical recurrence, as were those having undergone extravesical ureterectomy or laparoscopic RNU.

[1]  A. Vicens,et al.  Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma , 2010, BJU international.

[2]  S. Boorjian,et al.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology , 2005, BJU international.

[3]  J. Coleman,et al.  Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? , 2010, European urology.

[4]  T. O'brien,et al.  Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). , 2011, European urology.

[5]  A. Goel,et al.  Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of , 2012, European urology.

[6]  F. Montorsi,et al.  Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. , 2014, European urology.

[7]  C. Tulić,et al.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival , 2011, International Urology and Nephrology.

[8]  G. V. van Koeveringe,et al.  Functional detrusor myoplasty for bladder acontractility: long-term results. , 2011, The Journal of urology.

[9]  M. Babjuk,et al.  European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas, 2011 update , 2012 .

[10]  J. Patard,et al.  Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract , 2008, BJU international.

[11]  Wen-Jeng Wu,et al.  Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. , 2010, European urology.

[12]  K. Bensalah,et al.  Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. , 2009, European urology.

[13]  O. Cussenot,et al.  Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. , 2011, Urologic oncology.

[14]  K. Yoshimura,et al.  Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. , 2005, Urology.

[15]  H. D. Pearse,et al.  Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract , 1976, Cancer.

[16]  A. Ouzzane,et al.  Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract , 2009, BJU international.

[17]  F. Koga,et al.  Risk Factors for the Development of Bladder Transitional Cell Carcinoma following Surgery for Transitional Cell Carcinoma of the Upper Urinary Tract , 2001, Urologia Internationalis.

[18]  J. Stein,et al.  Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. , 2007, The Journal of urology.

[19]  L. Lacombe,et al.  Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience , 2011, BJU international.

[20]  S. Shariat,et al.  Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort , 2011, BJU international.

[21]  Wen-Jeng Wu,et al.  Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? , 2010, The Journal of urology.

[22]  H. Miyake,et al.  Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. , 2008, Urology.

[23]  M. Gallucci,et al.  Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. , 2009, European urology.

[24]  Y. Sugimura,et al.  Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma , 2008, International journal of urology : official journal of the Japanese Urological Association.

[25]  H. Villavicencio-Mávrich,et al.  Bladder neoplasms after nephroureterectomy: does the surgery of the lower ureter, transurethral resection or open surgery, influence the evolution? , 2002, European urology.

[26]  N. Masumori,et al.  Risk factors for the development of bladder cancer after upper tract urothelial cancer. , 2000, Urology.

[27]  C. Kwak,et al.  Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. , 2011, Urologic oncology.

[28]  H. Nishimatsu,et al.  Bladder recurrence of upper urinary tract cancer after laparoscopic surgery , 2006, Journal of surgical oncology.

[29]  A. Kawauchi,et al.  Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. , 2009, European urology.

[30]  K. Mita,et al.  Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. , 2007, Japanese journal of clinical oncology.